$ENDV
ENDONOVO THERAPEUTICS, INC.

2019 Q3 Form 10-Q Financial Statement

#000149315220022038 Filed on November 19, 2020

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2019 Q1
Revenue $54.04K $62.73K $44.95K
YoY Change 153.59% 527.29% 349.52%
Cost Of Revenue $8.925K $29.57K $7.711K
YoY Change 107.08%
Gross Profit $45.11K $33.16K $37.24K
YoY Change 165.38% 231.56%
Gross Profit Margin 83.48% 52.86% 82.85%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $162.6K $162.6K $162.5K
YoY Change -2.89% 1.61% 1.55%
% of Gross Profit 360.49% 490.35% 436.28%
Operating Expenses $1.336M $1.008M $850.2K
YoY Change 27.01% 21.44% -33.58%
Operating Profit -$1.291M -$974.8K -$813.0K
YoY Change 24.73% 18.88%
Interest Expense -$125.7K -$6.876M -$1.632M
YoY Change -97.47% 1085.54% -402.24%
% of Operating Profit
Other Income/Expense, Net -$114.9K -$6.863M
YoY Change
Pretax Income -$1.406M -$7.838M -$2.406M
YoY Change -76.36% 527.0% 288.1%
Income Tax
% Of Pretax Income
Net Earnings -$1.406M -$7.838M -$2.406M
YoY Change -76.36% 527.0% 288.1%
Net Earnings / Revenue -2602.19% -12494.29% -5352.88%
Basic Earnings Per Share -$1.81 -$13.57 -$4.99
Diluted Earnings Per Share -$1.81 -$13.57 -$4.99
COMMON SHARES
Basic Shares Outstanding 777.2K shares 577.5K shares 481.8K shares
Diluted Shares Outstanding 777.2K shares 577.5K shares 481.8K shares

Balance Sheet

Concept 2019 Q3 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.040K $547.5K $58.48K
YoY Change -99.24% 682.19% -41.52%
Cash & Equivalents $58.48K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $22.58K $29.94K
Prepaid Expenses
Receivables $11.28K $8.430K $10.32K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $38.89K $585.9K $68.79K
YoY Change -94.35% 485.9% -42.68%
LONG-TERM ASSETS
Property, Plant & Equipment $6.820K $7.000K $5.980K
YoY Change -11.89% -30.0% -40.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.375M $3.537M $3.697M
YoY Change -16.1% -15.39% -15.0%
TOTAL ASSETS
Total Short-Term Assets $38.89K $585.9K $68.79K
Total Long-Term Assets $3.375M $3.537M $3.697M
Total Assets $3.414M $4.123M $3.766M
YoY Change -27.55% -3.68% -15.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $346.2K $281.0K $198.9K
YoY Change -90.85% -93.35%
Accrued Expenses $3.515M $3.273M $3.255M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $7.133M $6.782M $6.276M
YoY Change -1.44% 10.63% 14.94%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.82M $20.21M $15.24M
YoY Change 13.45% 64.08% 24.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $155.0K $155.0K $155.0K
YoY Change 0.0% -3.13% -3.13%
Total Long-Term Liabilities $155.0K $155.0K $155.0K
YoY Change -88.25% -85.65% -81.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.82M $20.21M $15.24M
Total Long-Term Liabilities $155.0K $155.0K $155.0K
Total Liabilities $19.98M $20.37M $15.39M
YoY Change 6.31% 52.01% 17.58%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$16.57M -$16.25M -$11.62M
YoY Change
Total Liabilities & Shareholders Equity $3.414M $4.123M $3.766M
YoY Change -27.55% -3.68% -15.75%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$1.406M -$7.838M -$2.406M
YoY Change -76.36% 527.0% 288.1%
Depreciation, Depletion And Amortization $162.6K $162.6K $162.5K
YoY Change -2.89% 1.61% 1.55%
Cash From Operating Activities -$1.017M -$687.6K -$528.2K
YoY Change 22.1% -7.08% -10.47%
INVESTING ACTIVITIES
Capital Expenditures -$720.00 -$1.870K $0.00
YoY Change -169.9% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$720.00 -$1.870K
YoY Change -169.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 475.0K 1.179M $207.6K
YoY Change -66.71% 63.69% -65.41%
NET CHANGE
Cash From Operating Activities -1.017M -687.6K -$528.2K
Cash From Investing Activities -720.0 -1.870K
Cash From Financing Activities 475.0K 1.179M $207.6K
Net Change In Cash -542.5K 489.1K -$320.7K
YoY Change -191.16% -2545.25%
FREE CASH FLOW
Cash From Operating Activities -$1.017M -$687.6K -$528.2K
Capital Expenditures -$720.00 -$1.870K $0.00
Free Cash Flow -$1.016M -$685.8K -$528.2K
YoY Change 21.86% -7.33% -8.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1031247 USD
CY2019Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2002182 USD
CY2019Q2 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3134981 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-16246895 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-11624678 USD
CY2019Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
29954 USD
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
92084 USD
CY2019Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
37813 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
161720 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
54039 USD
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27559 USD
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33547 USD
us-gaap Net Income Loss
NetIncomeLoss
-11649967 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1406196 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-3848761 USD
CY2019Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-819675 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-4785167 USD
CY2019Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
693996 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3079075 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1291263 USD
us-gaap Operating Expenses
OperatingExpenses
3194586 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
1336377 USD
us-gaap Gross Profit
GrossProfit
115511 USD
CY2019Q3 us-gaap Gross Profit
GrossProfit
45114 USD
us-gaap Cost Of Revenue
CostOfRevenue
46209 USD
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
8925 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11649967 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1406196 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-19.00
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-19
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
613272 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
777249 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
613272 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
777249 shares
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
63036 USD
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
10746 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1003 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8570892 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-114933 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
USD
CY2019Q1 ENDV Valuation Of Stock Issued With Notes Payable
ValuationOfStockIssuedWithNotesPayable
26545 USD
CY2019Q3 ENDV Shares Issued With Lockup Agreements
SharesIssuedWithLockupAgreements
3788 USD

Files In Submission

Name View Source Status
0001493152-20-022038-index-headers.html Edgar Link pending
0001493152-20-022038-index.html Edgar Link pending
0001493152-20-022038.txt Edgar Link pending
0001493152-20-022038-xbrl.zip Edgar Link pending
endv-20200930.xml Edgar Link completed
endv-20200930.xsd Edgar Link pending
endv-20200930_cal.xml Edgar Link unprocessable
endv-20200930_def.xml Edgar Link unprocessable
endv-20200930_lab.xml Edgar Link unprocessable
endv-20200930_pre.xml Edgar Link unprocessable
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending